Piramal Pharma Reports Robust FY25 Financial Growth and Significant Sustainability Achievements
The announcement provides comprehensive financial results and detailed sustainability performance for the full financial year, demonstrating robust operational and strategic progress. These updates are critical for investor confidence, stakeholder engagement, and reflect the company's long-term value creation strategy.
The company reported strong financial growth for FY2025, including significant increases in revenue, net profit, and market capitalization, alongside substantial achievements in environmental (GHG reduction, renewable energy, waste, water conservation), social (women's representation, safety, CSR), and governance metrics. These indicate positive overall performance and strategic direction.
Piramal Pharma Limited (PPLPHARMA) has released its Sustainability Report for the financial year 2024-25 (April 1, 2024, to March 31, 2025), detailing strong financial performance and progress across its environmental, social, and governance (ESG) objectives. * Financial Highlights for FY2025: * Total revenue reached ₹9,151.18 Crore, marking an 11.99% year-on-year increase. * Net Profit increased 5x year-on-year to ₹91.13 Crore. * EBITDA margin rose to 17.26% from 17% in the previous year. * Market capitalization grew by 75% to ₹29,796 Crore. * Net debt to EBITDA improved substantially from 5.6 to 2.7. * Key Sustainability Achievements: * Achieved a 6% reduction in Scope 1 and 2 GHG emissions. * Increased renewable energy consumption by 7.8% compared to the previous year, with 20.1% of total energy sourced from bioenergy. * Achieved zero hazardous waste to landfill. * Saved over 2.10 Lakh kilolitres of freshwater. * Planted over 2,000 saplings, maintaining more than 30% green cover in Indian operations. * Customer satisfaction scores reached 85% in the CDMO business and 87% in the hospital generics business. * Successfully completed 36 regulatory inspections, including 2 by the USFDA, and 165 customer audits. * Increased women’s representation in the global workforce by 2.7%. * Achieved a 45% improvement in Lost Time Injury Rate (LTIR). * Spent ₹5.34 Crore on CSR projects, impacting 200 Million people across 112 aspirational districts. * The Board comprises 50% independent directors and 30% women representation. * 26.51% of critical suppliers were assessed on ESG criteria. The report is prepared in accordance with the Global Reporting Initiative (GRI) Universal Standards 2021, aligned with the United Nations Sustainable Development Goals (UN SDGs), and has undergone external assurance by DNV Business Assurance India Pvt Ltd. Commenting on the report, Nandini Piramal, Chairperson, and Peter DeYoung, CEO, Global Pharma, stated, "At Piramal Pharma, sustainability is a deliberate choice embedded in the way we operate, grow and contribute to the world around us. By innovating responsibly and growing sustainably, we are committed to creating lasting value for our business, our communities, and the planet."
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under sustainability. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.